Table 2.
Patient demographics and characteristics.
| Patients, N = 142 | Patients at academic hospitals, n = 133 | Patients at non-academic hospitals, n = 9 | p-value | |
|---|---|---|---|---|
| Demographics, median (IQR) | ||||
| Age (years) | 6.8 (3.1–12.5) | 6.2 (3.0–12.3) | 8.3 (5.6–14.3) | 0.16 |
| Weight (kg) | 22.1 (24.5–42.3) | 22.0 (13.9–42.5) | 24.3 (19.8–46.8) | 0.25 |
| Height (cm)a | 120.0 (96.0–154.5) | 120.0 (95.2–154.6) | 130.0 (112.8–162.0) | 0.26 |
| Oncologic/hematologic disease, n/N (%) | ||||
| ALL | 52/142 (36.6) | 49/133 (36.8) | 3/9 (33.3) | 1.00 |
| AML | 18/142 (12.7) | 16/133 (12.0) | 2/9 (22.2) | 0.32 |
| Hodgkin's lymphoma | 1/142 (0.7) | 1/133 (0.8) | 0/9 (0.0) | 1.00 |
| MDS/aplastic anemia | 2/142 (1.4) | 2/133 (1.5) | 0/9 (0.0) | 1.00 |
| Non-Hodgkin lymphoma | 12/142 (8.5) | 12/133 (9.0) | 0/9 (0.0) | 1.00 |
| Solid malignant tumor outside brain | 44/142 (31.0) | 42/133 (31.6) | 2/9 (22.2) | 0.72 |
| Malignant brain tumor | 7/142 (4.9) | 6/133 (4.5) | 1/9 (11.1) | 0.37 |
| Other | 6/142 (4.2) | 5/133 (3.8) | 1/9 (11.1) | 0.33 |
| State of disease, n/N (%) | ||||
| First diagnosis | 113/142 (79.6) | 106/133 (79.7) | 7/9 (77.8) | 1.00 |
| Relapse | 29/142 (20.4) | 27/133 (20.3) | 2/9 (22.2) | 1.00 |
| Additional data of interest, n/N (%) | ||||
| Neutropeniab | 71/140 (50.7) | 68/131 (51.9) | 3/9 (33.3) | 0.32 |
| Mucositis grade IIIc | 16/141 (11.3) | 16/132 (12.1) | 0/9 (0) | 0.60 |
| Severe graft-versus-host diseasec | 1/141 (0.7) | 0/132 (0) | 1/9 (11.1) | 0.064 |
| Central venous access devicec | 126/141 (89.4) | 119/132 (90.2) | 7/9 (77.8) | 0.25 |
| High-risk for fungal infectionc | 47/141 (33.3) | 46/132 (34.8) | 1/9 (11.1) | 0.27 |
| TMP/SMX prophylaxisc | 127/141 (90.1) | 120/132 (90.9) | 7/9 (77.8) | 0.22 |
| Colonization with multidrug-resistant organism, n/N (%) | ||||
| MRSA | 1/142 (0.7) | 1 (0.8) | 0/9 (0) | 1.00 |
| VRE | 1/142 (0.7) | 0 (0.0) | 1/9 (11.1) | 0.063 |
| Multi-drug resistant gram-negative organisms | 11/142 (7.7) | 11 (8.3) | 0/9 (0.0) | 1.00 |
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; IQR: interquartile range; MDS: myelodysplastic syndrome; MRSA: methicillin-resistant Staphylococcus aureus; TMP/SMX: trimethoprim/sulfamethoxazole; VRE: vancomycin-resistant enterococci.
a
3 cases unknown.
b
2 cases unknown.
c
1 case unknown; determinators were the total number of patients, when patients value was missing the patient was excluded for that value.